Immunocore Holdings plc ADR 2024年度报告

(Mark One) xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934For the fiscal year ended December 31, 2024or oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934For the period from________to________Commission File Number 001-39992Immunocore Holdings plc (Exact name of registrant as specified in its charter) Not Applicable (State or other jurisdiction of incorporation)(I.R.S. Employer Identification No.) 92 Park Drive Milton ParkAbingdon, Oxfordshire, United KingdomOX14 4RY (Address of principal executive offices)(Zip code) Tel: +44 1235 438600(Telephone Number) Title of each classTrading Symbol(s)Name of each exchange on whichregistered American Depositary Shares, eachrepresenting one ordinary share,nominal value £0.002 per shareIMCRThe Nasdaq Stock Market LLCOrdinary share, nominal value £0.002per share**The Nasdaq Stock Market LLC* *Not for trading, but only in connection with the listing of the American Depositary Shares on The NasdaqStock Market LLC. Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of theSecurities Act. x Yes o No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of theSecurities Exchange Act of 1934. oYes x No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirementsfor the past 90 days. x Yes o No Indicate by check mark whether the registrant has submitted electronically every Interactive Data Filerequired to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during thepreceding 12 months (or for such shorter period that the registrant was required to submit such files). xYes o No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “largeaccelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” inRule 12b-2 of the Exchange Act. Large acceleratedfiler xAccelerated filer oNon- acceleratedfiler oSmaller reportingcompany oEmerging growthcompany o If an emerging growth company, indicate by check mark if the registrant has elected not to use theextended transition period for complying with any new or revised financial accounting standards providedpursuant to Section 13(a) of the Exchange Act. o Indicate by check mark whether the registrant has filed a report on and attestation to its management’sassessment of the effectiveness of its internal control over financial reporting under Section 404(b) of theSarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issuedits audit report. x If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether thefinancial statements of the registrant included in the filing reflect the correction of an error to previouslyissued financial statements. o Indicate by check mark whether any of those error corrections are restatements that required a recoveryanalysis of incentive-based compensation received by any of the registrant’s executive officers during therelevant recovery period pursuant to §240.10D-1(b). o Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).oYes x No The aggregate market value of the voting and non-voting ordinary shares held by non-affiliates of theregistrant, based upon $33.89, the closing price of the registrant’s American Depositary Shares on theNasdaqGlobal Market on June 28,2024(the last business day of the registrant’s most recentlycompleted second fiscal quarter) was approximately $1.6 billion. As of January 31, 2025, the registrant had 50,068,126ordinary shares (including ordinary shares in theform of American Depositary Shares) outstanding, par value £0.002, shares consisting of (i) 49,333,729voting ordinary shares and 734,397 non-voting ordinary shares. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s proxy statement to be filed with the Securities and Exchange Commissionpursuantto Regulation 14A in connection with the registrant’s 2025 Annual General Meeting ofShareholders are incorporated by reference into Part III of this Annual Report on Form 10-K. Such proxystatement will be filed with the Securities and Exchange Commission not later than 120 days following theend of the registrant’s fiscal year ended December 31, 2024. TABLE OF CONTENTS Page PART IV136ITEM 15.EXHIBITS AND FINANCIAL STATEMENT SCHEDULES136ITEM 16.FORM 10-K SUMMARY138SIGNATURES139